Printed from the IBC Life Sciences Web site on March 12, 2014 1:04 AM ET.
Page location: http://www.ibclifesciences.com/Vaccines/overview.xml
June 03-05, 2013 · Durham Convention Center · Durham, NC
WORLD'S FIRST EGG-FREE INFLUENZA VACCINE
Manon M.J. Cox, Ph.D., President and CEO, Protein Sciences Corporation
CELL CULTURE-BASED VACCINES
Rino Rappuoli, Ph.D., Global Head, Vaccines Research, Novartis Vaccines & Diagnostics, Italy
NEW INFLUENZA VACCINES FOR PANDEMIC PREPAREDNESS
Robert C. Huebner, Ph.D., Acting Director Influenza Division, HHS/ASPR/BARDA
WHAT'S HAPPENING ON THE VACCINE ADJUVANT FRONT?
Nikolai Petrovsky, Ph.D., Endocrinology Department, Flinders Medical Centre, Australia
Do you have new data to share? Enhance your conference experience by presenting a poster - it could lead to exciting opportunities for your company.
Join our priority contact list and receive the latest event news.
IBC's 4th Annual Vaccine Development & Production Summit brings you the newest data on ways to improve yield and reduce cost in vaccine production. Hear discussions on novel, creative strategies such as alternative cell lines, QbD for process control and validation, novel adjuvants and new delivery concepts. Gain insight on continuous improvements in upstream and downstream processing to purify viruses and increase yield.
Exclusive Interview with Manon M.J. Cox, President and CEO, Protein Sciences Corporation
Protein Sciences Corporation developed the world's first recombinant, highly purified, egg-free influenza vaccine, Flublok®, which the FDA regards as a technological advance in the manufacturing of an influenza vaccine.
Listen to a 7 minute exclusive interview with Manon M.J. Cox.:
Throughout our research for this conference it was clear that the many aspects of development are crucial right now. That's why this year's program has an emphasis on these issues. Hear about process improvements that use QbD, the process modernization of an anthrax vaccine with single-use technologies, as well as novel formulation with insect cell-based cultures and needle-free delivery.
This conference gives you the opportunity to learn what industry leaders are doing to stay competitive in the surging vaccines market. You will learn how to enhance your process and improve yield, while reducing costs. Delve into novel (and needleless) vaccine delivery platforms. Gain applicable knowledge from case studies on process development and manufacturing challenges, and quality-by-design implementation. Discover how single-use deployment can modify your production process and increase throughput.